Literature DB >> 27135282

Efficacy and possible mechanisms of topical tranexamic acid in melasma.

S J Kim1, J-Y Park1, T Shibata1, R Fujiwara2, H Y Kang1.   

Abstract

BACKGROUND: Tranexamic acid (TA) has been suggested as an effective treatment for melasma. AIM: To investigate the effects and mechanism of action of topical TA in the treatment of melasma.
METHODS: In this study, 23 participants with melasma applied a 2% TA formulation to the whole face for 12 weeks. Clinical effects were evaluated using the modified Melasma Area and Severity Index (mMASI) and a chromameter. Skin biopsies were obtained from 10 participants to evaluate pigmentation, vascularity and the expression levels of possible paracrine factors contributing to the effect of TA.
RESULTS: Most of the participants had mild melasma, with mMASI of < 5. The mMASI scores significantly improved in 22 of 23 participants after application. The L* values were increased and the a* values were decreased in both lesional and perilesional normal skin. Fontana-Masson staining showed a significant decrease in melanin content in the epidermis. The number of CD31-positive vessels and the expression of the vascular endothelial growth factor both tended to decrease. Endothelin (ET)-1 was found to be downregulated with TA.
CONCLUSIONS: Topical TA is effective for melasma. This immunohistochemical study found that suppression of ET-1 could be one of the mechanisms of action of TA on melasma.
© 2016 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27135282     DOI: 10.1111/ced.12835

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  10 in total

1.  Therapeutic Effect of Microneedling with Platelet-rich Plasma Versus Microneedling with Tranexamic Acid for Melasma.

Authors:  Khaled Gharib; Fawzia Farag Mostafa; Soheir Ghonemy
Journal:  J Clin Aesthet Dermatol       Date:  2021-08-01

Review 2.  Topical Treatments for Melasma and Their Mechanism of Action.

Authors:  Valeria González-Molina; Alicia Martí-Pineda; Noelani González
Journal:  J Clin Aesthet Dermatol       Date:  2022-05

3.  Comparison of efficacy of Tranexamic Acid Mesotherapy versus 0.9% normal Saline for Melasma; A split face study in a Tertiary Care Hospital of Karachi.

Authors:  Sana Kaleem; Rabia Ghafoor; Sidra Khan
Journal:  Pak J Med Sci       Date:  2020 Jul-Aug       Impact factor: 1.088

4.  Therapeutic Effects of Topical Tranexamic Acid in Comparison with Hydroquinone in Treatment of Women with Melasma.

Authors:  Najmolsadat Atefi; Behzad Dalvand; Mahammadreza Ghassemi; Golnaz Mehran; Amir Heydarian
Journal:  Dermatol Ther (Heidelb)       Date:  2017-07-26

5.  Tranexamic Acid for Adults with Melasma: A Systematic Review and Meta-Analysis.

Authors:  Lei Zhang; Wei-Qiang Tan; Qing-Qing Fang; Wan-Yi Zhao; Qi-Ming Zhao; Jie Gao; Xiao-Wei Wang
Journal:  Biomed Res Int       Date:  2018-11-06       Impact factor: 3.411

6.  Targeting delivery and minimizing epidermal diffusion of tranexamic acid by hyaluronic acid-coated liposome nanogels for topical hyperpigmentation treatment.

Authors:  Ying Liu; Yue Han; Tingting Zhu; Xianglei Wu; Wenxin Yu; Jiafang Zhu; Ying Shang; Xiaoxi Lin; Tianlan Zhao
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

7.  Tranexamic acid reduces endometrial cancer effects through the production of angiostatin.

Authors:  Keiichi Hiramoto; Yurika Yamate
Journal:  J Cancer       Date:  2022-03-06       Impact factor: 4.207

8.  Comparison of the Efficacy of Intralesional Tranexamic Acid Versus Topical 4% Hydroquinone in Treating Melasma.

Authors:  Shigref Mushtaq; Syeda Sibgha Naz; Muhammad Rizwan; Nudrat Jehangir Khan; Obed Ullah; Anjum Muhammad
Journal:  Cureus       Date:  2022-08-29

Review 9.  Melasma: an Up-to-Date Comprehensive Review.

Authors:  Oluwatobi A Ogbechie-Godec; Nada Elbuluk
Journal:  Dermatol Ther (Heidelb)       Date:  2017-07-19

10.  Tranexamic Acid Inhibits Angiogenesis and Melanogenesis in Vitro by Targeting VEGF Receptors.

Authors:  Jian-Wei Zhu; Ya-Jie Ni; Xiao-Yun Tong; Xia Guo; Xiao-Ping Wu; Zhong-Fa Lu
Journal:  Int J Med Sci       Date:  2020-03-25       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.